MedTrace Logo

A Study to Investigate the Efficacy of Pain Bloc-R in Healthy Participants With Non-pathological Aches and Discomfort

NCT03965819 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2019-08-13

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled, cross-over pilot study to investigate the efficacy of Pain Bloc-R in healthy participants with non-pathological aches and discomfort. The study will have 3 study periods. During each study period, eligible participants will consume either Pain Bloc-R, comparator product, or placebo for 7 days during each study period (1 product per study period), with a 1-week washout period in between each period. The primary objective is the comparison of change in unresolved aches and discomfort from pre-supplement to Day 7 between the Pain Bloc-R, comparator, and placebo, as assessed by the Brief Pain Inventory (BPI) questionnaire.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Pain Bloc-R

Herbal Supplement containing Vit D3, Vit B6, Vit B12, White Willow Bark, Angelica Root, Acetyl L-carnitine HCl, Caffeine, L-Theanine, Benfotiamine, and L-Tetrahydropalmatine

OTHER

Active Comparator - Acetaminophen

DIN 02447479 Encapsulated for Blinding Purposes

OTHER

Placebo

No active ingredients

Sponsors & Collaborators

  • KGK Science Inc.

    collaborator INDUSTRY

  • LifeSeasons Inc.

    lead INDUSTRY

Principal Investigators

  • David Crowley, MD · Qualified Investigator

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-30
Primary Completion
2019-08-09
Completion
2019-08-09

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03965819 on ClinicalTrials.gov